Helse Stavanger Hf
🇸🇪Sweden
Clinical Trials
95
Active:8
Completed:54
Trial Phases
5 Phases
Phase 1:3
Phase 2:6
Phase 3:4
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials
Not Applicable
40 (67.8%)Phase 2
6 (10.2%)Phase 4
6 (10.2%)Phase 3
4 (6.8%)Phase 1
3 (5.1%)Bridging Affect Consciousness, Mentalization and Trauma- Exploring an Integrative Treatment Approach for Personality Disorder (PD).
Not Applicable
Not yet recruiting
- Conditions
- Personality Disorder, BorderlinePersonality TraitPersonality DisorderPersonality TypePersonality Disorder, AvoidantAffect ConsciousnessMentalizationReflective FunctioningPTSDPTSD - Post Traumatic Stress Disorder
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 300
- Registration Number
- NCT06983002
- Locations
- 🇳🇴
Stavanger University Hospital, Stavanger, Rogaland, Norway
Phenserine on the Alzheimer's Treatment Horizon, Study 1
Phase 1
Not yet recruiting
- Conditions
- Alzheimer DiseaseMild Cognitive Impairment
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 16
- Registration Number
- NCT06774261
Prevalence of Alzheimer's Disease Pathology in the Community
Completed
- Conditions
- Dementia of Alzheimer TypeAlzheimer DiseaseMild Cognitive ImpairmentPathologyBiomarker in Early Diagnosis
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 9663
- Registration Number
- NCT06719453
REBECCA-3 Study, Research on Breast Cancer Induced Chronic Conditions Supported by Causal Analysis of Multi-source Data
Active, not recruiting
- Conditions
- Cancer Related Fatigue
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 40
- Registration Number
- NCT06435091
- Locations
- 🇳🇴
Stavanger University Hospital, Stavanger, Norway
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
Phase 2
Recruiting
- Conditions
- Alzheimer DiseaseCognitive Decline, Mild
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 200
- Registration Number
- NCT06362707
- Locations
- 🇳🇴
University Hospital of North Norway, Tromsø, Nordland, Norway
🇳🇴Haugesund Hospital, Haugesund, Rogaland, Norway
🇳🇴Stavanger University Hospital, Stavanger, Rogaland, Norway
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
No news found